RETRACTION: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study (Retraction of Vol 5, Pg 785, 2017)

被引：0
|
作者：
Waterer, Grant [1 ]
机构：
[1] Lancet Resp Med, London EC2Y 5AS, England
来源：
LANCET RESPIRATORY MEDICINE | 2024年 / 12卷 / 04期
关键词：
D O I：
10.1016/S2213-2600(24)00029-8
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：262 / 263
页数：2
相关论文
共 50 条
  • [41] Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study (vol 21, pg 796, 2020)
    Abou-Alfa, G. K.
    Macarulla, T.
    Javle, M. M.
    LANCET ONCOLOGY, 2020, 21 (10): : E462 - E462
  • [42] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, H. C.
    Wang, S.
    Skljarevski, V
    Ahl, J.
    Millen, B.
    Aurora, S. K.
    Yang, J.
    HEADACHE, 2017, 57 (08): : 1336 - 1337
  • [43] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    CEPHALALGIA, 2017, 37 : 338 - 338
  • [44] A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [45] Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study
    Mori, Etsuro
    Ikeda, Manabu
    Iseki, Eizo
    Katayama, Sadao
    Nagahama, Yasuhiro
    Ohdake, Megumi
    Takase, Takao
    PSYCHOGERIATRICS, 2024, 24 (03) : 542 - 554
  • [46] EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)
    Ruperto, N.
    Chertok, E.
    Dehoorne, J.
    Horneff, G.
    Kallinich, T.
    Louw, I.
    Compeyrot-Lacassagne, S.
    Lauwerys, B.
    Martin, N.
    Marzan, K.
    Knibbe, W.
    Martin, R.
    Zhu, X.
    Whelan, S.
    Pricop, L.
    Martini, A.
    Lovell, D. J.
    Brunner, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 145 - 146
  • [47] Protocol for a multicentre, double-blind, randomised, placebo-controlled trial of riociguat on peak cardiac index during exercise in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty (THERAPY-HYBRID-BPA trial)
    Shimokawahara, Hiroto
    Inami, Takumi
    Kubota, Kayoko
    Taniguchi, Yu
    Hashimoto, Hiroya
    Saito, Akiko M.
    Sekimizu, Masahiro
    Matsubara, Hiromi
    BMJ OPEN, 2023, 13 (07):
  • [48] Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Cluster Headache: Results from 3-Month Double-Blind Treatment
    Oakes, T. M.
    Dodick, D. W.
    Goadsby, P. J.
    Lucas, C.
    Jensen, R.
    Bardos, J.
    Martinez, J.
    Zhou, C.
    Aurora, S. K.
    Yang, J.
    Conley, R.
    HEADACHE, 2019, 59 : 19 - 20
  • [49] Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Tang, Jean Y.
    Ally, Mina S.
    Chanana, Anita M.
    Mackay-Wiggan, Julian M.
    Aszterbaum, Michelle
    Lindgren, Joselyn A.
    Ulerio, Grace
    Rezaee, Melika R.
    Gildengorin, Ginny
    Marji, Jackleen
    Clark, Charlotte
    Bickers, David R.
    Epstein, Ervin H., Jr.
    LANCET ONCOLOGY, 2016, 17 (12): : 1720 - 1731
  • [50] Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial (vol 5, pg 864, 2017)
    Dandona, P.
    Mathieu, C.
    Phillip, M.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (12): : E8 - E8
12345